FDA OKs additional indication for SPECT agent AdreView

03/24/2013 | AuntMinnie.com (free registration)

The FDA has allowed the use of GE Healthcare's SPECT imaging agent AdreView, also known as iobenguane I-123, in the evaluation of myocardial sympathetic innervation in patients with New York Heart Association class II or III heart failure and left-ventricular ejection fraction at or lower than 35%. The company said the agent has the potential to detect the likelihood that patients' heart failure will advance.

View Full Article in:

AuntMinnie.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD